VRDN

23.01

3.32% 0.74

Dopo l'orario di chiusura: 23.31 0.30 +1.30%

Viridian Therapeutics Inc (VRDN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$22.27

Aprire:

$22.46

Volume 24 ore:

1.65M

Relative Volume:

2.10

Capitalizzazione di mercato:

$1.88B

Reddito:

$305.00K

Utile/perdita netta:

$-328.98M

Rapporto P/E:

-6.0078

EPS:

-3.83

Flusso di cassa netto:

$-309.60M

1 W Prestazione:

+5.50%

1M Prestazione:

+23.31%

6M Prestazione:

+81.90%

1 anno Prestazione:

-3.28%

Intervallo 1D:

$21.79

$23.07

Intervallo di 1 settimana:

$20.71

$23.07

Portata 52W:

$9.90

$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Nome

Viridian Therapeutics Inc

Settore

Healthcare (1140)

Industria

Biotechnology (637)

Telefono

617.272.4600

Indirizzo

221 CRESCENT STREET, WALTHAM

Dipendente

143

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

VRDN's Discussions on Twitter

Confronta VRDN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VRDN Viridian Therapeutics Inc	23.01	1.70B	305.00K	-328.98M	-309.60M	-3.83
VRTX Vertex Pharmaceuticals Inc	408.61	105.69B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	481.07	61.52B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	569.17	60.69B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	837.28	50.05B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	318.02	35.25B	4.56B	-176.77M	225.30M	-1.7177

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-25	Ripresa	Jefferies	Buy
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-11-25	Iniziato	TD Cowen	Buy
2024-09-11	Reiterato	Needham	Buy
2024-06-11	Iniziato	Wolfe Research	Outperform
2024-06-06	Iniziato	Goldman	Buy
2024-05-09	Downgrade	B. Riley Securities	Buy → Neutral
2024-05-09	Downgrade	Ladenburg Thalmann	Buy → Neutral
2023-06-14	Iniziato	BTIG Research	Buy
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-05-30	Iniziato	RBC Capital Mkts	Outperform
2023-04-17	Iniziato	Wells Fargo	Overweight
2023-03-30	Iniziato	Stifel	Buy
2022-12-19	Iniziato	Cowen	Outperform
2022-12-19	Iniziato	Needham	Buy
2022-12-16	Iniziato	Credit Suisse	Outperform
2022-12-01	Iniziato	H.C. Wainwright	Buy
2022-06-23	Iniziato	B. Riley Securities	Buy
2021-11-18	Iniziato	SVB Leerink	Outperform
2021-10-12	Iniziato	Evercore ISI	Outperform
2021-01-25	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie

Oct 16, 2025

Is this a good reentry point in Viridian Therapeutics Inc.Market Performance Summary & Growth Focused Entry Reports - newser.com

Oct 16, 2025

Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Oct 16, 2025

Is Viridian Therapeutics Inc. building a consolidation base2025 Technical Overview & Technical Pattern Based Signals - newser.com

Oct 16, 2025

How buybacks impact Viridian Therapeutics Inc. stock value2025 Stock Rankings & AI Forecasted Stock Moves - newser.com

Oct 16, 2025

Oct 15, 2025

Is Viridian Therapeutics Inc. stock dividend yield sustainableAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com

Oct 15, 2025

Oct 14, 2025

What machine learning models say about Viridian Therapeutics Inc.Dollar Strength & Fast Gain Stock Trading Tips - newser.com

Oct 14, 2025

How Viridian Therapeutics Inc. stock reacts to bond yieldsMarket Performance Report & Weekly Return Optimization Plans - newser.com

Oct 14, 2025

Tools to monitor Viridian Therapeutics Inc. recovery probability2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com

Oct 14, 2025

Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - The Globe and Mail

Oct 14, 2025

Oct 13, 2025

Is Viridian Therapeutics Inc. stock reversal real or fakeJuly 2025 Action & Daily Volume Surge Signals - newser.com

Oct 13, 2025

Using Ichimoku Cloud for Viridian Therapeutics Inc. technicals2025 Trading Recap & Fast Exit and Entry Strategy Plans - newser.com

Oct 13, 2025

What candlestick patterns are forming on Viridian Therapeutics Inc.Forecast Cut & Free Technical Pattern Based Buy Signals - newser.com

Oct 13, 2025

Can machine learning forecast Viridian Therapeutics Inc. recoveryJuly 2025 Highlights & Low Risk Investment Opportunities - newser.com

Oct 13, 2025

Is Viridian Therapeutics Inc. stock attractive for growth ETFsMarket Movement Recap & Fast Entry Momentum Alerts - newser.com

Oct 13, 2025

Oct 12, 2025

Why Viridian Therapeutics Inc. is moving todayWeekly Trade Recap & Scalable Portfolio Growth Methods - newser.com

Oct 12, 2025

Oct 11, 2025

Is Viridian Therapeutics Inc. (1S1) stock protected from inflationMarket Risk Report & Pattern Based Trade Signal System - newser.com

Oct 11, 2025

Viridian Therapeutics’ (VRDN) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World

Oct 11, 2025

Oct 10, 2025

Is Viridian Therapeutics Inc. stock safe for conservative investors2025 Dividend Review & Scalable Portfolio Growth Ideas - newser.com

Oct 10, 2025

Viridian Therapeutics supports key conferences with sponsorship initiative - Traders Union

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reaffirms "Sell (D-)" Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat

Oct 09, 2025

Oct 06, 2025

Real time alert setup for Viridian Therapeutics Inc. performanceBear Alert & Real-Time Volume Surge Alerts - newser.com

Oct 06, 2025

Oct 05, 2025

Will Viridian Therapeutics Inc. (1S1) stock beat growth indexesJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com

Oct 05, 2025

Oct 04, 2025